Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;28(10):1370-5.
doi: 10.1002/mds.25535. Epub 2013 Jul 1.

Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation

Affiliations
Free PMC article

Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation

Aikaterina Angeli et al. Mov Disord. 2013 Sep.
Free PMC article

Abstract

Variation in the genetic risk(s) of developing Parkinson's disease (PD) undoubtedly contributes to the subsequent phenotypic heterogeneity. Although patients with PD who undergo deep brain stimulation (DBS) are a skewed population, they represent a valuable resource for exploring the relationships between heterogeneous phenotypes and PD genetics. In this series, 94 patients who underwent DBS were screened for mutations in the most common genes associated with PD. The consequent genetic subgroups of patients were compared with respect to phenotype, levodopa (l-dopa), and DBS responsiveness. An unprecedented number (29%) of patients tested positive for at least 1 of the currently known PD genes. Patients with Parkin mutations presented at the youngest age but had many years of disease before needing DBS, whereas glucocerebrosidase (GBA) mutation carriers reached the threshold of needing DBS earlier, and developed earlier cognitive impairment after DBS. DBS cohorts include large numbers of gene positive PD patients and can be clinically instructive in the exploration of genotype-phenotype relationships.

Keywords: Parkinson's disease; deep brain stimulation; genetics; heterogeneity; phenotype.

PubMed Disclaimer

References

    1. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol. 2002;249:138–145. - PubMed
    1. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57–71. - PMC - PubMed
    1. Schapira AH. Mitochondrial diseases. Lancet. 2012;379:1825–1834. - PubMed
    1. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain. 2013;136:374–384. - PubMed
    1. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641–649. - PMC - PubMed

Publication types

MeSH terms